Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Antiinfective agent stubs
Oteseconazole
Другие языки:

Oteseconazole

Подписчиков: 0, рейтинг: 0

Oteseconazole
Oteseconazole.png
Clinical data
Trade names Vivjoa
Other names VT-1161
License data
Routes of
administration		 By mouth
Drug class Antifungal
ATC code
Legal status
Legal status
Identifiers
  • (2R)-2-(2,4-Difluorophenyl)-1,1-difluoro-3-(tetrazol-1-yl)-1-[5-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-2-yl]propan-2-ol
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
ECHA InfoCard 100.277.989
Chemical and physical data
Formula C23H16F7N5O2
Molar mass 527.403 g·mol−1
3D model (JSmol)
  • C1=CC(=CC=C1C2=CN=C(C=C2)C([C@](CN3C=NN=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)OCC(F)(F)F
  • InChI=1S/C23H16F7N5O2/c24-16-4-7-18(19(25)9-16)21(36,11-35-13-32-33-34-35)23(29,30)20-8-3-15(10-31-20)14-1-5-17(6-2-14)37-12-22(26,27)28/h1-10,13,36H,11-12H2/t21-/m0/s1
  • Key:IDUYJRXRDSPPRC-NRFANRHFSA-N

Oteseconazole, sold under the brand name Vivjoa, is a medication used for the treatment of vaginal yeast infections.

It was approved for medical use in the United States in April 2022. It was developed by Mycovia Pharmaceuticals.

Society and culture

Names

Oteseconazole is the international nonproprietary name (INN).

Further reading

External links

  • "Oteseconazole". Drug Information Portal. U.S. National Library of Medicine.
  • Clinical trial number NCT03562156 for "A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) (VIOLET)" at ClinicalTrials.gov
  • Clinical trial number NCT03561701 for "A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) (VIOLET)" at ClinicalTrials.gov
  • Clinical trial number NCT03840616 for "Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections (ultraVIOLET)" at ClinicalTrials.gov



Новое сообщение